Moreover, FGFR4 mutations were associated with a higher TMB value (P < 0.0001) and a higher PD-L1 score (P = 0.0082) in advanced NSCLC patients in cBioPortal. This evidence concerns the gene FGFR4 and non-small cell lung carcinoma.